Durvalumab showed significant improvements in event-free survival and overall survival in muscle-invasive bladder cancer patients compared to chemotherapy alone. The phase 3 NIAGARA study involved ...

At month 6, the overall high-grade complete response rate was 72% (13 of 18 Researchers reported positive safety and efficacy data for TARA-002, an investigational treatment for patients with ...

TAR-200 monotherapy achieved an 83.5% complete response rate in BCG-unresponsive high-risk NMIBC patients, with a high insertion success rate of 98.8%. The treatment was well tolerated, with most ...

The trial targets intermediate-risk non-muscle invasive bladder cancer, focusing on superficial stage A, primarily low-grade tumors. Cretostimogene grenadenorepvec is compared to surveillance in a ...

Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer. Combining androgen deprivation therapy with novel hormonal ...

The study analyzed mCRPC patients with HRRm treated with olaparib, focusing on real-world treatment outcomes and biomarker testing patterns. Patients were stratified by treatment line and prior ...

Belzutifan's safety profile was evaluated in 576 patients with advanced RCC across four clinical trials, revealing a high incidence of adverse events. Anemia was the most common adverse event, ...

PT217 targets DLL3 and CD47, receiving FDA fast track and orphan drug designations for neuroendocrine prostate cancer and carcinoma. The SKYBRIDGE trial evaluates PT217's safety, tolerability, and ...

Cretostimogene grenadenorepvec demonstrated a 74.5% overall complete response rate in high-risk BCG-unresponsive NMIBC patients. At 12 months, 97.3% of patients were free from progression to ...

The S1011 trial found no benefit and higher adverse events with extended lymph node dissection in muscle-invasive bladder cancer. The retrospective study analyzed 740 patients, revealing minimal ...